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As a clinician and academician, I have been discouraged by the discourse surrounding use of patient-centric variable dosing regimens using vascular endothelial growth factor inhibitors (VEGF-i) and off-label medication for chorioretinal neovascular diseases. Presently, 94.3% of retina specialists employ a variable dosing treatment regimen for the treatment of neovascular age-related macular degeneration (nAMD) and only 5.7% adhere to monthly VEGF-i therapies as performed in the registration trials of the U.S. Food and Drug Administration (FDA)-approved VEGF-i. 1 Furthermore, approximately 50% of the market for these diseases is dominated by bevacizumab (Avastin; Genentech, South San Francisco, CA), an off-label VEGF-i, whereas approximately 50% are two VEGF-i that have gone through the rigorous FDA approval process. 2 Before we should entertain notions of societal benefit of a therapeutic protocol, we must first assess 3 components of therapy: efficacy, safety, and cost. If the therapy does not work, safety and cost are no longer relevant as the therapy will not be adopted.
EFFICACY
How did we get to the point where an off-label medication and suboptimal dosing strategies have come to dominate? Ophthalmology, in general, and the retina subspecialty particularly, is justifiably proud of its accomplishments and contributions to medicine, therapeutic development, and prevention of blindness. Two trials, the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS), set a high bar for the design, implementation, and dissemination of knowledge from randomized, controlled trials (RCTs), establishing diagnostic and treatment protocols that were memorized and adhered to by a generation of ophthalmologists for the treatment of diabetic macular edema (DME) and proliferative retinopathy. [3] [4] [5] The DRS and ETDRS served as the framework for all subsequent RCTs in ophthalmology and retina. Around the time I graduated from ophthalmology residency in 1999, two of the four leading causes of blindness were AMD and diabetes in white patients and cataract and glaucoma in black patients. 6 In the nearly 20 years since then, we have seen wide-spread availability of VEGF-i limit blindness and, in some cases, restore vision in patients with nAMD, DME, and retinal vascular occlusive (RVO) disease. This 20-year period may represent the most prolific era of vision loss reduction from a therapeutic viewpoint in the Western world. Unfortunately, as we will see, these gains have been short-lived, resulting in short-term gains Continuous dosing treatment regimens with vascular growth factor inhibitors (VEGF-i) as evaluated by randomized controlled clinical trials for age-related macular degeneration, retinal vein occlusion, and diabetic macular edema offer superior visual acuity and anatomic outcomes compared to noncontinuous dosing regimens. Although, at first appearance, these differences seem to be marginal, they accrue over time, resulting in real loss of function that is significant. Similarly, arguments have been made that off-label use of repackaged bevacizumab (Avastin; Genentech, South San Francisco, CA) offers an equivalent safety profile to professionally packaged U.S. Food and Drug Administration (FDA)-approved VEGF-I, while ignoring that most retina specialists obtain bevacizumab from compounding pharmacies, exposing their patients to rare but catastrophic outcomes such as cluster endophthalmitis. Use of professionallypackaged, FDA-approved VEGF-i and continuous dosing treatment regimens have demonstrated their safety and efficacy, and our patients should be offered these as a first-line therapy before considering other medications or dosing regimens.
as opposed to locking in long-term gains, similar to the VEGF-i agents themselves, which are more vasculostatic than vasculocidal.
The first domino to fall was nAMD, with the release of results from the MARINA trial conclusively demonstrating the efficacy of 24 monthly ranibizumab (Lucentis; Genentech, South San Francisco, CA) intravitreal injections versus placebo control in subjects with nAMD. 7 Unlike the groundbreaking trials that preceded -MPS, 8, 9 TAP, 10 and VI-SION 11 -treated subjects in the MARINA trial actually experienced mean visual gain with therapy (Table 1) . 7 These results were largely duplicated in follow-on trials and with another VEGF-i agent, aflibercept (Eylea; Regeneron, Tarrytown, NY) (Table 1). [12] [13] [14] Next up was RVO. Monthly ranibizumab for 6 months for patients with macular edema from branch and central retinal vein occlusions (BRVO/ CRVO) far outperformed sham (Table 2) . 15, 16 In similar trial designs, monthly aflibercept outperformed laser and sham, respectively, for macular edema secondary to BRVO and CRVO, respectively (Table  2) . 17, 18 Third on the list was DME. Both ranibizumab monthly and aflibercept monthly and bimonthly (after five loading doses) were superior to sham and laser, respectively (Table 3) . 20, 21 It is clear from the data (Tables 1-3) at 1 year that both agents are efficacious using continuous dosing strategies ranging from 4 weeks to 8 weeks for nAMD, RVO, and DME. Functional outcome data in the form of vision gains and preservation supporting monthly and/or bimonthly VEGF-i far exceeded previous trial data with laser and photodynamic therapy treatments, [3] [4] [5] [8] [9] [10] [11] and we had entered into a renaissance in retinal vascular disease therapeutics. 7, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Concurrent with these large industry-led trials, a revolution was occurring in clinical practice, spurred by two innovations: 1) the introduction of off-label intravitreal bevacizumab, and 2) widespread adoption of optical coherence tomography (OCT)-guided variable dosing regimens of VEGFi. 2, 22, 23 Bevacizumab was so clearly effective and variable dosing regimens so clearly intuitive that a number of trials were conducted to evaluate the relative effectiveness of bevacizumab, variable dosing strategies, or both versus ranibizumab and/or aflibercept and continuous dosing. These included the CATT, IVAN, HORIZON-AMD, VIEW-Extension for nAMD; HORIZON-RVO and SCORE 2 for RVO; and Protocol T for DME. [24] [25] [26] [27] [28] [29] [30] [31] [32] Visual acuity outcomes at year 1 (month 6 for SCORE 2) were similar for on-label FDA-approved agents (aflibercept and ranibizumab) versus off-label bevacizumab and also for dosing regimens (continuous versus variable) (Tables 1-3) . 24, [26] [27] [28] [29] [30] [31] [32] Before proceeding, we need to discuss the concept of noninferiority. The three types of trial outcomes -superiority, equivalence, and noninferiority -are intuitive. In superiority trials, one is trying to achieve an outcome that is better than a standard treatment; in equivalence trials, one is trying to show two treatments are equal; and in noninferiority trials, one is trying to demonstrate that given a prespecified margin, one treatment is not substantially different than the standard treatment. 37 Table 1 illustrates this very nicely. In MA-RINA and ANCHOR (both superiority trials), we see that ranibizumab is superior to both sham and photodynamic therapy at year 1. This last point is key, in that outcomes refer to a specific time point, in this case, year 1.
It is also clear from the data (Tables 1-3 ) that at year 1 endpoints using continuous dosing strategies ranging from 4 to 8 weeks for nAMD, RVO, and DME, all three agents are efficacious. Editorials were written that a new day was dawning, and that patient-centric, individualized care with bevacizumab was going to prevent blindness, reduce costs, and lead to improved patient satisfaction. [33] [34] [35] [36] It is worth examining what happened after the continuous dosing schedule was abandoned. In general, as physicians deviated from the continuous dosing schedules to variable dosing, primarily guided by fluid status on optical coherence tomography (OCT), gradual declines in visual acuity were noticed, often to levels as low as before treatment initiation, with concomitant gains of fluid on OCT ( Table 1) .
The CATT extension trial demonstrated the greatest loss of effect due to dosing change: greater than two lines of vision at year 5 when physicians were left to employ variable dosing intervals per their clinical practice (Table 1) . 27 The VIEW 1 extension study provided data for additional 2 years of follow-up with aflibercept beyond the VIEW studies. 29 At year 4, even though a modified pro re nata regimen with mandatory treatments every 8 to 12 weeks resulted in lesser vision decline (approximately three letters), the data indicated that the watch-and-treat approach is not optimum for maintaining vision over time (Table 1) . 29 The rebuttal to this loss of maintenance of visual acuity gain is that the long-term studies themselves did not utilize continuous dosing and it is impossible to predict what might have happened. Maybe 
BCVA = best-corrected visual acuity; RBZ = ranibizumab; IAI = intravitreal aflibercept injection; BVZ = bevacizumab
so; however, Peden et al. reported that continuous dosing (every 4 weeks to 8 weeks, minimum annual injections ≥ 6.5) maintained a gain of +14 letters at year 5 (n = 109), +12.2 letters at year 6 (n = 75), and +12.1 letters at year 7 (n = 44) in a study evaluating patients in clinical practice. 38 Though small numbers of patients were included, these results closely mirror the Year 1 results from MARINA and VIEW trials.
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SAFETY
What about safety? No significant safety concerns were raised for any of the VEGF-i agents in these trials of nAMD, RVO, and DME. Aflibercept, bevacizumab, and ranibizumab appear to have a limited systemic safety concern and most local side-effects can be attributed to the injection. 7, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [24] [25] [26] [27] [29] [30] [31] [32] It is interesting to note, however, that in CATT, Protocol T, and SCORE-2, bevacizumab was obtained from the University of Pennsylvania pharmacy, which was then repackaged into separate sterile glass vials. 24, 31, 32 Most retina physicians obtain their bevacizumab from compounding pharmacies delivered in plastic syringes, which are prepared in a largely unregulated environment, 39, 40 prompting advice by legal experts for physicians to use only FDA-approved products for disease treatment when one is available. 41 One commonly noted complication attributed to plastic syringes is intravitreal silicone oil droplets following injection of VEGF-i. 42 Other concerns have been related to variable quality of the preparation and bacterial and/or fungal contamination. [44] [45] [46] With regard to infectious endophthalmitis, there is no specific increase of cases of endophthalmitis on an incidence basis between bevacizumab and ranibizumab in more than 10,000 injections, a rate of 0.029%. 46 This has been the oft-cited basis for lack of difference in safety profile.
However, the interpretation of infectious endophthalmitis risk as presented in these studies is incomplete and possibly misleading because it does not take into account the multiple clusters of cases. The Pew Charitable Trusts evaluated illnesses and death secondary to compounded and repackaged medications during the 15-year period (2001 to 2015) and identified 1,074 cases. 47 In 36 cases, endophthalmitis secondary to bevacizumab with vision loss occurred, with the following compounding errors: 26 cases of identified contamination, five cases of unintended presence of another medication, and five unknown errors. [48] [49] [50] [51] It is interesting to note here that no cases of cluster infectious endophthalmitis following intravitreal injection using an FDA-approved product have ever been reported in either the registration trials or postmar- keting surveillance. 5, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [27] [28] [29] [30] This is a phenomenon that has been attributed to human error due to sloppy technique at the compounding pharmacies. 52 It has even been opined that endophthalmitis is not a "never event." 53 What is a never event? In their editorial "The Quest to Eliminate 'Never Events,'" Lum and Schachat noted that never events were "serious, largely preventable, and of concern to both the public and health care providers," quoting from the National Quality Forum report of 2002. 54, 55 Although I agree with the contention that infectious endophthalmitis is not a never event, I disagree that cluster infectious endophthalmitis due to contamination is not a never event. The data support the notion that cluster infectious endophthalmitis due to contamination can be largely mitigated by simply using FDA-approved medications.
If we use the concept of existential risk -something that represents a risk to the future of humanity -the equivalent of existential risk in ophthalmology is something that represents a threat to the future of vision in an individual. 56 Similar to cluster endophthalmitis risk, existential risk is predominantly caused by humans (global warming, nuclear war). 52, 56 There are two conceptual ways of dealing with existential risk: maximin and maxipok. Bostrum defined the maximin approach as choosing for the "best worst-case scenario," 56 whereas in the maxipok (maximize the possibility of an OK outcome) the goal is to select any outcome that avoids "existential catastrophe." 56 I think that we can agree that clusters of loss of vision, blindness, and enucleation secondary to errors in compounding and repackaging represent an "existential catastrophe" to vision, regardless of the incidence of such clusters when there exists an alternative that has not demonstrated a propensity for such events. [47] [48] [49] [50] [51] If such time should come to pass when all physicians have access to professionally repackaged bevacizumab (and other ocular medications), the calculus could change.
COSTS
Ranibizumab has an average wholesale price of $1,950 for 0.5 mg dosing and $1,360 for 0.3 mg dosing. Aflibercept costs $1,850. Since the safety question was not adequately addressed for off-label bevacizumab, the cost ranging from $60 to $250 per dose must be weighed against the known proven risks of existential catastrophe of cluster endophthalmitis and the attendant risks of vision loss, blindness, and enucleation. [47] [48] [49] [50] [51] 
CONCLUSION
From the above data and Table 1 , it is clear that it is disingenuous to make the argument that it is not clinically significant to have one to two letters' difference at any given time point. Vision loss can be continuous, cumulative, and irreversible. What is a two-letter difference at year 1 is two lines or more at years 4 and 5. To paraphrase the late Senator Everett Dirksen, "A few letters here, a few letters there; pretty soon you're talking real vision [loss] ." This is sometimes rationalized as a patient-driven expectation; however, when queried after being presented with the facts, patients choose for vision and increased injections. 57 In a neat bit of circular logic, one of the indications for discontinuing therapy is lack of functional stabilization or lack of improvement, an outcome more often associated with bevacizumab and variable dosing strategies. 13, 27, 29 In today's clinical retina practice, the twin pillars of bevacizumab and OCT-guided variable dosing strategies are buttressed by financial arguments and noninferiority outcomes at a year 1 endpoint. Unfortunately, the trial endpoints do not correspond with the vast majority of patients requiring ongoing treatment for years or longer.
SUMMARY
Retina specialists have played a role in the creation and continuing improvement of the modern RCT, with a long-term commitment to adhering to these RCT protocol therapies in clinical practice. Recently, two unique events -the availability of low-cost, off-label bevacizumab with a proven therapeutic effect and the advent of OCT-guided variable VEGF-i dosing strategies -have upset the traditional adherence to these protocols, at some cost to our patients' visual acuity status. Although the visual acuity differences based on VEGF-i agent and/or dosing regimen may be statistically negligible (≤ 5 letters) at a given time point (eg, year 1), the differences increase over the longer term. The data support this conclusion. Lack of adherence to these established protocols and FDA-approved drugs is simply encouraging a soft landing into the harsh reality of legal blindness over time.
